MaxCyte, Inc. ( MXCT ) NASDAQ Global Select

Cena: 2.22 ( 2.53% )

Aktualizacja 06-24 20:26
NASDAQ Global Select
Branża: Medical - Devices
Statystyki
Dywidendy
Rekomendacje
Wyceny
Wskaźniki
Analiza techniczna

Notowania:

Informacje o spółce:
Sektor: Zdrowie
Branża: Medical - Devices
Zatrudnienie: 143
Giełda: NASDAQ Global Select
Ilość akcji w obrocie: 88%
Ilość akcji: 103 710 000
Debiut giełdowy: 2021-07-30
WWW: https://maxcyte.com
CEO: Mr. Maher Masoud
Adres: 9713 Key West Avenue
Siedziba: 20850 Rockville
ISIN: US57777K1060
Opis firmy:

Maxcyte, Inc., Global Life Sciences Company, angażuje się w odkrywanie, rozwój i komercjalizację terapii komórkowych nowej generacji. Jego produkty obejmują Expert ATX, statyczny instrument elektroporacyjny do transfekcji małej i średniej w skali; Expert STX, elektroporacja przepływu do produkcji białka i opracowywania leku, a także ekspresję celów terapeutycznych do testów komórkowych; Expert GTX, elektroporacja przepływu do transfekcji na dużą skalę w zastosowaniach terapeutycznych; oraz ekspert VLX do bardzo dużej inżynierii komórkowej. Firma dostarcza również zespoły przetwarzania jednorazowego (PA) do komórek procesowych i elektroporacyjnych; oraz akcesoria obsługujące PA, takie jak rozwiązanie buforu elektroporacyjnego i protokoły oprogramowania. Firma została zarejestrowana w 1998 roku i ma siedzibę w Rockville w stanie Maryland.

Wskaźniki finansowe
Kapitalizacja (USD) 236 558 740
Aktywa: 248 612 000
Cena: 2.22
Wskaźnik Altman Z-Score: 5.6
Stabilny (niskie ryzyko bankructwa)
Dywidenda: 0
P/E: -5.6
Ilość akcji w obrocie: 88%
Średni wolumen: 885 503
Ilość akcji 106 318 535
Wskaźniki finansowe
Przychody TTM 45 601 000
Zobowiązania: 35 310 000
Przedział 52 tyg.: 2.01 - 5.2
Piotroski F-Score: 2
Słaby (niska jakość finansowa)
EPS: -0.4
P/E branży: 26.8
Beta: 1.16
Raport okresowy: 2025-08-06
WWW: https://maxcyte.com
Zarząd
Imie i Nazwisko Stanowisko Wynagrodzenie Rok urodzenia
Dr. J. Stark Thompson Ph.D. Consultant 84 708 1942
Mr. Maher Masoud President, Chief Executive Officer & Executive Director 650 984 1975
Mr. Ronald Evan Holtz CPA, Ph.D. Executive Vice President of Administration 649 385 1958
Mr. Douglas J. Swirsky CFA, CPA Chief Financial Officer 607 416 1969
Mr. Douglas Arthur Doerfler Founder 2 338 348 1956
Mr. Jay Gelfman Senior Vice President of Operations 0 0
Mr. Jack Horgan Vice President of Corporate Development 0 0
Mr. David Sandoval Senior Vice President, General Counsel & Corporate Secretary 0 1978
Mr. Thomas Michael Ross Executive Vice President of Global Sales 0 1961
Ms. Jill Mayer Senior Vice President of Human Resources 0 0
Wiadomości dla MaxCyte, Inc.
Tytuł Treść Źródło Aktualizacja Link
MaxCyte Signs Strategic Platform License with TG Therapeutics to Advance its Autoimmune Cell Therapeutics Programs ROCKVILLE, Md., Feb. 12, 2025 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (Nasdaq: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell-based therapeutics, today announced they are entering into a strategic platform license (SPL) with TG Therapeutics, a fully integrated, commercial stage, biopharmaceutical company focused on the acquisition, development and commercialization of novel treatments for B-cell diseases. globenewswire.com 2025-02-12 04:00:00 Czytaj oryginał (ang.)
MaxCyte to Report Fourth Quarter and Full Year 2024 Financial Results on March 11, 2025, and Participate in Upcoming Investor Conference ROCKVILLE, Md., Feb. 07, 2025 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics, today announced that it will release financial results for the fourth quarter and full year 2024 after the U.S. market close on Tuesday, March 11th, 2025. Company management will host a conference call to discuss financial results at 4:30 p.m. Eastern Time. globenewswire.com 2025-02-07 04:00:00 Czytaj oryginał (ang.)
Glancy Prongay & Murray LLP Announces Investigation of MaxCyte, Inc. (MXCT) NEW YORK--(BUSINESS WIRE)--Glancy Prongay & Murray LLP (“GPM”) announces its investigation of MaxCyte, Inc. (NASDAQ: MXCT) concerning the Company and its directors' and officers' possible violations of state laws. If you own MaxCyte stock, would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Tom Kennedy, of GPM, 230 Park Avenue, Suite 358, New York, NY 10169 at tkennedy@glanc. businesswire.com 2025-01-30 12:36:00 Czytaj oryginał (ang.)
MaxCyte® Acquires SeQure Dx to Broaden Cell Engineering Offerings with On-target and Off-target Editing Assessments ROCKVILLE, Md., Jan. 30, 2025 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (Nasdaq: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing solutions to advance the discovery, development and commercialization of next-generation cell therapeutics announced today the acquisition of SeQure Dx, a market leader of on-target and off-target editing assessment services for cell and gene therapies. globenewswire.com 2025-01-30 04:00:00 Czytaj oryginał (ang.)
MaxCyte: Building the Future of Cell and Gene Therapy Innovation MaxCyte Inc. NASDAQ: MXCT is a global developer of next-generation cell therapies. They provide crucial technology for cell and gene therapies. marketbeat.com 2025-01-23 09:00:03 Czytaj oryginał (ang.)
Recent Price Trend in MaxCyte (MXCT) is Your Friend, Here's Why If you are looking for stocks that are well positioned to maintain their recent uptrend, MaxCyte (MXCT) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen. zacks.com 2025-01-22 11:50:31 Czytaj oryginał (ang.)
All You Need to Know About MaxCyte (MXCT) Rating Upgrade to Strong Buy MaxCyte (MXCT) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term. zacks.com 2025-01-15 15:00:44 Czytaj oryginał (ang.)
MaxCyte Announces Preliminary Unaudited Fourth Quarter and Full Year 2024 Financial Results ROCKVILLE, Md., Jan. 13, 2025 (GLOBE NEWSWIRE) -- MaxCyte, Inc. , (Nasdaq: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics, today provided a preliminary update on financial results for the fourth quarter and full year ended December 31, 2024. globenewswire.com 2025-01-13 05:05:00 Czytaj oryginał (ang.)
MaxCyte Announces Retirement of Board Member Art Mandell ROCKVILLE, Md., Dec. 22, 2024 (GLOBE NEWSWIRE) -- MaxCyte, Inc. , (Nasdaq: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics, today announced that Art Mandell has retired from his position as a member of the Board of Directors of MaxCyte effective December 31, 2024. Mr. Mandell has served on the Board since 2006 and has been an integral part of MaxCyte's growth and strategic direction. Upon Mr. Mandell's retirement, MaxCyte will have nine directors. globenewswire.com 2024-12-23 04:00:00 Czytaj oryginał (ang.)
MaxCyte Announces Streamlined Operations and Raises 2024 Revenue Guidance ROCKVILLE, Md., Dec. 08, 2024 (GLOBE NEWSWIRE) -- MaxCyte, Inc. , (Nasdaq: MXCT; LSE: MXCT), a leading cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics, today announced the completion of an internal operational review, initiated earlier this year following the appointment of Maher Masoud as President and Chief Executive Officer. This “bottom-up” review focused on optimizing new product development, manufacturing, commercial execution, and capital allocation to enhance efficiency and align resources with strategic priorities. As part of an effort to streamline operations, the company made adjustments to its workforce which affected 21 positions, reflecting approximately 15% of its personnel globally, including both directly employed individuals and those engaged through third-party employer-of-record (EOR) arrangements. This adjustment is designed to improve accountability, better align personnel resources with the company's goals, and position MaxCyte for long-term growth. globenewswire.com 2024-12-09 04:00:00 Czytaj oryginał (ang.)
MaxCyte Celebrates 25 Years of Innovation Driving Cell Engineering-Based Therapeutics Since 1999, MaxCyte's non-viral cell engineering innovations have helped launch pioneering cell and gene therapy projects Since 1999, MaxCyte's non-viral cell engineering innovations have helped launch pioneering cell and gene therapy projects globenewswire.com 2024-11-13 10:05:00 Czytaj oryginał (ang.)
MaxCyte, Inc. (MXCT) Q3 2024 Earnings Call Transcript MaxCyte, Inc. (MXCT) Q3 2024 Earnings Call Transcript seekingalpha.com 2024-11-07 00:01:58 Czytaj oryginał (ang.)
MaxCyte, Inc. (MXCT) Reports Q3 Loss, Tops Revenue Estimates MaxCyte, Inc. (MXCT) came out with a quarterly loss of $0.11 per share versus the Zacks Consensus Estimate of a loss of $0.13. This compares to loss of $0.11 per share a year ago. zacks.com 2024-11-06 21:00:56 Czytaj oryginał (ang.)
MaxCyte Reports Third Quarter 2024 Financial Results and Updates Full Year 2024 Guidance ROCKVILLE, Md., Nov. 06, 2024 (GLOBE NEWSWIRE) -- MaxCyte, Inc. (NASDAQ: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development, and commercialization of next-generation cell therapeutics, today announced its financial results for the third quarter ended September 30, 2024, and updated its 2024 guidance. globenewswire.com 2024-11-06 18:05:00 Czytaj oryginał (ang.)
MaxCyte to Participate in Two Upcoming Investor Conferences ROCKVILLE, Md., Oct. 31, 2024 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (Nasdaq: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell-based therapeutics, today announced Company management will participate at two upcoming investor conferences. globenewswire.com 2024-10-31 10:05:00 Czytaj oryginał (ang.)
MaxCyte (MXCT) Upgraded to Strong Buy: What Does It Mean for the Stock? MaxCyte (MXCT) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy). zacks.com 2024-10-16 17:05:24 Czytaj oryginał (ang.)
MaxCyte Appoints Cynthia Collins to its Board of Directors ROCKVILLE, Md., Oct. 15, 2024 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (Nasdaq: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell-based therapeutics and innovative bioprocessing applications, today announced the appointment of Cynthia Collins to the Company's Board of Directors as a non-executive director, effective October 14, 2024. Collins will serve on the board's compensation committee. Following her appointment, MaxCyte's total Board of Directors will increase to 10 members. globenewswire.com 2024-10-15 12:05:00 Czytaj oryginał (ang.)
MaxCyte to Report Third Quarter 2024 Financial Results on November 6, 2024 ROCKVILLE, Md., Oct. 11, 2024 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics and innovative bioprocessing applications, today announced that it will release financial results for the third quarter 2024 after the U.S. market close on Wednesday, November 6th, 2024. Company management will host a conference call to discuss financial results at 4:30 p.m. Eastern Time. globenewswire.com 2024-10-11 12:05:00 Czytaj oryginał (ang.)
MaxCyte Appoints Ali Soleymannezhad as Chief Commercial Officer ROCKVILLE, Md., Oct. 10, 2024 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (Nasdaq: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell-based therapeutics and innovative bioprocessing applications, today announced the appointment of Ali Soleymannezhad as Chief Commercial Officer, effective as of September 11, 2024. globenewswire.com 2024-10-10 12:05:00 Czytaj oryginał (ang.)
Maxcyte: Reaching Financial Inflection With CASGEVY Ramp Up MaxCyte, Inc.'s stock performance has been disappointing since its 2021 IPO, despite positive business developments and a 34% revenue growth. The company faces high capital requirements for modest revenue gains, but has a substantial cash reserve to sustain operations. FDA approval of CASGVEY validates MaxCyte's platform, with potential multi-billion dollar opportunities and significant future revenue. seekingalpha.com 2024-10-04 21:19:52 Czytaj oryginał (ang.)